$PBH (Prestige Brands Holdings, Inc.)

$PBH {{ '2016-05-12T13:15:08+0000' | timeago}} • Webcast

$PBH said that the company's goal is to launch 3 to 5 new products each year. In FY16, the company launched new products like Dramamine, Nix, Compound W, Little Remedies, Goody's and Fiber Choice.

$NEOG {{ '2017-09-19T13:39:04+0000' | timeago}} • Announcement

Food safety company $NEOG reported a 20.57% increase in its 1Q18 earnings, driven by a revenue jump of 13.88% in the quarter. Net income rose to $11.91MM, or $0.31 per share from $9.88MM, or $0.26 per share a year earlier. Revenue rose to $95.25MM from $83.64MM a year ago.

$EVHC {{ '2017-09-19T12:30:35+0000' | timeago}} • Announcement

As part of $EVHC's organizational changes, Karey Witty, a veteran healthcare executive, has been appointed to the new role of EVP and COO, effective Oct 2, 2017. Kevin Eastridge, currently CAO, will succeed Claire Gulmi as CFO, effective same day.

$EVHC {{ '2017-09-19T12:24:50+0000' | timeago}} • Announcement

$EVHC announced the authorization of a program to repurchase up to $250MM of its common stock, which represents approx 4% of its current market capitalization.

$PRXL {{ '2017-09-18T13:38:17+0000' | timeago}} • Announcement

$PRXL shareholders have approved the proposed acquisition of the company by certain investment funds affiliated with Pamplona Capital Management. Under the terms of the acquisition, Pamplona will acquire all outstanding shares of PAREXEL for $88.10 per share in cash. The closing of the transaction is anticipated on or about Sept 29, 2017.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$CLX {{ '2017-09-13T13:01:19+0000' | timeago}} • Announcement

$CLX said its BoD declared a quarterly dividend of 84 cents per share on the company's common stock. The dividend is payable on Nov. 13, 2017, to stockholders of record on Oct. 25, 2017.

$MYL {{ '2017-09-08T21:46:48+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. Pfizer is continuing to work with the FDA to resolve the points raised in the warning letter regarding Pfizer’s manufacturing of the EpiPen products and Mylan will do whatever it can to support this process.

$MYL {{ '2017-09-08T21:46:14+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. The letter was issued in connection with FDA's inspection of Pfizer’s pharmaceutical manufacturing facility located in Brentwood, Missouri, where the EpiPen products are manufactured.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

$PG {{ '2017-09-07T15:46:41+0000' | timeago}} • Announcement

$PG issued statement in response to a white paper from Trian Fund Management. $PG is well positioned to maximize long-term shareholder value through balanced top-line growth, bottom-line growth and cash efficiency. The board strongly recommended that stockholders vote the Blue proxy card to maintain its momentum and continue advancing its plan.

$JNJ {{ '2017-09-06T18:27:40+0000' | timeago}} • Announcement

Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of $JNJ, received FDA approval for a new 32 mg tablet for oral suspension for TRACLEER for use in pediatric patients aged three years and older, suffering from high blood pressure in the arteries of the lungs. The medication will be available from 4Q17.

$MDCO {{ '2017-08-30T13:09:58+0000' | timeago}} • Announcement

$MDCO said the FDA has approved Vabomere (meropenem and vaborbactam) for injection for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.

$PFE {{ '2017-08-29T14:05:59+0000' | timeago}} • Announcement

$PFE and $BMY presented investigational Eliquis data for patients with non-valvular atrial fibrillation undergoing cardioversion. The outcomes measured in EMANATE, a Phase 4 clinical trial, were the occurrence of acute stroke, systemic embolism, major bleeding, clinically relevant non-major bleeding and all-cause death.

$AGN {{ '2017-08-29T10:53:21+0000' | timeago}} • Announcement

$AGN and its subsidiaries reached a settlement regarding its litigation with Famy Care Ltd. relating to the company's patent covering Restasis (Cyclosporine Ophthalmic Emulsion). All Famy Care litigation regarding Restasis patents will be dismissed and Famy Care will terminate its pending petitions for Inter Parties Review.

$PRXL {{ '2017-08-28T22:48:19+0000' | timeago}} • Announcement

For 4Q17, $PRXL’s service revenue increased 3.8% to $557.2MM compared with 4Q16. On a segment basis, service revenue was $432.3MM in Clinical Research Services, $50MM in PAREXEL Consulting and $74.9MM in PAREXEL Informatics.

$PRXL {{ '2017-08-28T22:44:05+0000' | timeago}} • Announcement

$PRXL reported a decrease in 4Q17 earnings. Net income was $29.9MM or $0.58 per share compared to $42.7MM or $0.80 per share in 4Q16. Adjusted net income was $52.2MM or $1.02 per share in 4Q17. Total revenues grew to $647.6MM from $625.5MM last year.

$JNJ {{ '2017-08-28T15:56:47+0000' | timeago}} • Announcement

$JNJ said results from a Phase 3 study found that the XARELTO plus aspirin 100 mg once daily significantly reduced the risk of major cardiovascular (CV) events including CV death, heart attack or stroke by 24% in patients with stable coronary and/or peripheral artery disease, compared to aspirin alone. The study was conducted on 27,395 patients.

$PG {{ '2017-08-28T14:47:31+0000' | timeago}} • Announcement

$PG strongly recommended that shareholders vote to support the company's Board by voting the Blue Proxy Card "For" all its highly qualified Director nominees. The company highlighted winning strategy and world-class board in letter to shareholders.

$MDCO {{ '2017-08-28T12:09:36+0000' | timeago}} • Announcement

$MDCO and $ALNY announced positive data from the ORION-1 Phase II study of Inclisiran, an investigational, drug for the treatment of high cholesterol. The companies added that there were no deaths or serious adverse events during the extended observation period.

Recent Transcripts

ACET (Aceto Corp.)
Friday, August 25 2017 - 1:00pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
EVHC (Envision Healthcare Holdings, Inc.)
Tuesday, August 8 2017 - 12:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
CLX (The Clorox Company)
Thursday, August 3 2017 - 5:30pm
CHD (Church & Dwight Co. Inc.)
Thursday, August 3 2017 - 2:00pm
SHPG (Shire plc)
Thursday, August 3 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
PG (The Procter & Gamble Company)
Thursday, July 27 2017 - 12:30pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
CL (Colgate-Palmolive Co.)
Friday, July 21 2017 - 3:00pm
NEOG (Neogen Corp.)
Tuesday, July 18 2017 - 3:00pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, May 11 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm

AlphaGraphics you may like